ALK-Abelló Logo

ALK-Abelló

Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.

ALK | CO

Overview

Corporate Details

ISIN(s):
DK0061802139
LEI:
529900SGCREUZCZ7P020
Country:
Denmark
Address:
Bøge Alle 6-8, 2970 Hørsholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ALK-Abelló is a global pharmaceutical company specializing in the research, development, and manufacturing of allergy immunotherapy (AIT) products. A pioneer in the field for over a century, the company focuses on creating treatments that address the underlying cause of allergies, rather than merely managing symptoms. Its portfolio encompasses a range of evidence-based AIT products, including tablets, drops, and injections, as well as emergency treatments for severe allergic reactions like anaphylaxis. ALK's primary therapeutic areas are respiratory allergies, food allergies, and anaphylaxis. The company is committed to scientific innovation and expanding access to its solutions, such as needle-free adrenaline treatments, to improve the lives of people with allergies worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 17:17
Regulatory News Service
Danish 102.5 KB
2025-11-12 17:17
Earnings Release
Danish 3.3 KB
2025-11-12 17:17
Regulatory News Service
English 104.1 KB
2025-11-12 17:17
Earnings Release
English 2.8 KB
2025-09-17 09:44
M&A Activity
Danish 174.5 KB
2025-09-17 09:44
M&A Activity
Danish 10.0 KB
2025-09-17 09:44
M&A Activity
English 8.9 KB
2025-09-17 09:44
M&A Activity
English 274.6 KB
2025-08-21 07:30
Earnings Release
English 11.5 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Interim Report
English 505.8 KB
2025-08-21 07:30
Earnings Release
English 12.0 KB
2025-08-12 14:45
Earnings Release
Danish 103.0 KB
2025-08-12 14:45
Earnings Release
Danish 3.7 KB
2025-08-12 14:45
Earnings Release
English 108.6 KB

Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALK-Abelló

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALK-Abelló via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.